Articles

Lilly’s Cyramza gets new marketing approval

Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.

Read More

Alzheimer’s tests present dilemma of knowing the future

While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.

Read More

Covance shareholder sues over $6.1B LabCorp deal

A Covance Inc. investor contends in a lawsuit that the drug-testing company’s board erred in relying on what the shareholder called Goldman Sachs Group Inc.’s conflict-tainted advice. Covance has major laboratory operations in Indianapolis.

Read More

New type of cholesterol drug shows promise in study

The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.

Read More

Lechleiter: It’s morning at Eli Lilly

Lilly CEO John Lechleiter kicked off the company’s quarterly conference call with investors and analysts by declaring an end to the “unprecedented challenge” that Lilly lived through the past four years.

Read More